Cancer

Illumina completes the divestiture of GRAIL

GRAIL spin-off complete; GRAIL to begin regular way trading as "GRAL" on June 25Illumina to issue second quarter 2024 results…

7 months ago

Thermal Cyclers Market Worth 1.86 Billion 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.

JERSEY CITY, N.J., June 24, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report…

7 months ago

Dovetail Genomics and AGRF Announce Transformative Partnership Set to Advance Genomic Research in Australasia

Collaboration Establishes AGRF as Premier Provider of Dovetail's Cutting-Edge Genomic Technologies, Boosting Innovation and Access Across Australia and New Zealand…

7 months ago

MY DR NOW Expands to Maricopa, Bringing Accessible Healthcare to the Community

MARICOPA, Ariz.--(BUSINESS WIRE)--MY DR NOW, a leader in innovative healthcare solutions, is excited to announce the opening of its new…

7 months ago

SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland,…

7 months ago

Juniper Biologics Expands Distribution Rights for Caris Life Sciences’ Molecular Profiling in the Middle East and Africa

SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on…

7 months ago

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July…

7 months ago

C&N Teams Raise Over $98,000 for Local Senior Citizens

WELLSBORO, Pa., June 21, 2024 /PRNewswire/ -- (Citizens & Northern Corporation, NASDAQ: CZNC) – C&N, a leading community-oriented financial services institution, is…

7 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)

LEXINGTON, KY / ACCESSWIRE / June 21, 2024 / NX Development Corp. (NXDC) is pleased to announce a significant milestone.…

7 months ago

Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial

100% of patients enrolled achieved a partial response or betterMilder and less frequent drug-related adverse events were observed compared to…

7 months ago